CRNX
Price
$45.28
Change
+$0.49 (+1.09%)
Updated
Feb 6 closing price
Capitalization
4.64B
18 days until earnings call
Intraday BUY SELL Signals
CYTK
Price
$62.34
Change
+$2.10 (+3.49%)
Updated
Feb 6 closing price
Capitalization
7.62B
24 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRNX vs CYTK

Header iconCRNX vs CYTK Comparison
Open Charts CRNX vs CYTKBanner chart's image
Crinetics Pharmaceuticals
Price$45.28
Change+$0.49 (+1.09%)
Volume$2M
Capitalization4.64B
Cytokinetics
Price$62.34
Change+$2.10 (+3.49%)
Volume$1.74M
Capitalization7.62B
CRNX vs CYTK Comparison Chart in %
View a ticker or compare two or three
VS
CRNX vs. CYTK commentary
Feb 09, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Hold and CYTK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 09, 2026
Stock price -- (CRNX: $45.28 vs. CYTK: $62.34)
Brand notoriety: CRNX and CYTK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 158% vs. CYTK: 91%
Market capitalization -- CRNX: $4.64B vs. CYTK: $7.62B
CRNX [@Biotechnology] is valued at $4.64B. CYTK’s [@Biotechnology] market capitalization is $7.62B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.26B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileCYTK’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • CYTK’s FA Score: 0 green, 5 red.
According to our system of comparison, both CRNX and CYTK are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 4 TA indicator(s) are bullish while CYTK’s TA Score has 5 bullish TA indicator(s).

  • CRNX’s TA Score: 4 bullish, 5 bearish.
  • CYTK’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than CRNX.

Price Growth

CRNX (@Biotechnology) experienced а -9.33% price change this week, while CYTK (@Biotechnology) price change was -1.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.30%. For the same industry, the average monthly price growth was -2.98%, and the average quarterly price growth was +31.79%.

Reported Earning Dates

CRNX is expected to report earnings on Feb 26, 2026.

CYTK is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($7.62B) has a higher market cap than CRNX($4.64B). CYTK YTD gains are higher at: -1.889 vs. CRNX (-2.728). CRNX has higher annual earnings (EBITDA): -474.16M vs. CYTK (-646.17M). CRNX has more cash in the bank: 1.09B vs. CYTK (963M). CRNX has less debt than CYTK: CRNX (49.1M) vs CYTK (1.2B). CYTK has higher revenues than CRNX: CYTK (87.2M) vs CRNX (1.54M).
CRNXCYTKCRNX / CYTK
Capitalization4.64B7.62B61%
EBITDA-474.16M-646.17M73%
Gain YTD-2.728-1.889144%
P/E RatioN/AN/A-
Revenue1.54M87.2M2%
Total Cash1.09B963M113%
Total Debt49.1M1.2B4%
FUNDAMENTALS RATINGS
CRNX vs CYTK: Fundamental Ratings
CRNX
CYTK
OUTLOOK RATING
1..100
719
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
5366
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
4844
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRNX's Valuation (50) in the Pharmaceuticals Major industry is in the same range as CYTK (50) in the Biotechnology industry. This means that CRNX’s stock grew similarly to CYTK’s over the last 12 months.

CRNX's Profit vs Risk Rating (53) in the Pharmaceuticals Major industry is in the same range as CYTK (66) in the Biotechnology industry. This means that CRNX’s stock grew similarly to CYTK’s over the last 12 months.

CRNX's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as CYTK (100) in the Biotechnology industry. This means that CRNX’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (44) in the Biotechnology industry is in the same range as CRNX (48) in the Pharmaceuticals Major industry. This means that CYTK’s stock grew similarly to CRNX’s over the last 12 months.

CYTK's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that CYTK’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXCYTK
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
81%
MACD
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 25 days ago
75%
Bullish Trend 11 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
79%
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signal:
Gain/Loss:
CYTK
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ROFCX13.590.48
+3.66%
Royce Small-Cap Opportunity Consult
CNWCX94.542.06
+2.23%
American Funds New World 529C
IYCEX16.910.36
+2.18%
Nomura Core Equity Fund Class R
BTIRX166.113.21
+1.97%
DWS Equity 500 Index R6
JIAIX9.830.08
+0.82%
JHancock Multi-Asset High Income I

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+1.09%
XNCR - CRNX
60%
Loosely correlated
+7.30%
NUVL - CRNX
55%
Loosely correlated
+2.67%
DYN - CRNX
55%
Loosely correlated
+1.51%
IDYA - CRNX
55%
Loosely correlated
+1.26%
RLAY - CRNX
53%
Loosely correlated
+9.45%
More

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IONS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IONS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+3.49%
IONS - CYTK
64%
Loosely correlated
+3.62%
MLYS - CYTK
48%
Loosely correlated
+5.53%
IDYA - CYTK
46%
Loosely correlated
+1.26%
NEVPF - CYTK
45%
Loosely correlated
N/A
CRNX - CYTK
44%
Loosely correlated
+1.09%
More